What is PathOtrak?
PathOtrak specializes in rapid foodborne pathogen detection, offering the fastest testing solutions available, with results in as little as two hours. Their proprietary Next Generation Extraction (NGE) System is designed to significantly reduce incubation times and meets USDA and FDA compliance standards. The company targets critical industries including fresh produce, beef, poultry, and environmental sampling, providing cost-effective testing that can reduce lab consumable expenses by up to 50%. PathOtrak's commitment to swift and dependable pathogen identification positions it as a frontrunner in pathogen detection innovation.
How much funding has PathOtrak raised?
PathOtrak has raised a total of $2.8M across 3 funding rounds:
Other Financing Round
$300K
Other Financing Round
$300K
Debt
$2.2M
Other Financing Round (2023): $300K with participation from Tedco
Other Financing Round (2024): $300K led by Tedco
Debt (2025): $2.2M, investors not publicly disclosed
Key Investors in PathOtrak
Tedco
TEDCO, the Maryland Technology Development Corporation, focuses on fostering an inclusive entrepreneurial innovation ecosystem to drive economic empowerment. They invest in and support the growth of technology and life science-based companies within Maryland.
What's next for PathOtrak?
The recent major strategic investment signals a new phase of growth and market penetration for PathOtrak. This capital infusion is expected to accelerate the scaling of their NGE System, enhance research and development for further technological advancements, and expand their market reach within the food safety sector. The company's focus on efficiency and compliance is likely to drive broader adoption of its solutions, reinforcing its position as a leader in pathogen detection.
See full PathOtrak company page
